Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
BMC Complement Altern Med ; 16: 207, 2016 Jul 11.
Article in English | MEDLINE | ID: mdl-27402114

ABSTRACT

BACKGROUND: Mesenteric phlebosclerosis (MP) is a disease characterized by fibrotic change or calcification of the mesenteric vein. Recently, there has been an increase in case reports of MP related to herbal medicine usage. Long-term intake of gardenia fruit (GF) is suspected as a possible cause. However, many GF users do not develop this disease and the association between GF and MP remains unclear. In this study, we investigated for the first time the dosage of GF used by patients with and without MP. METHODS: We used a medical chart review study design to assess the association between GF and MP. We reviewed patients with a history of intake of herbal medicines containing GF. Among these patients, we selected patients who were examined by colonoscopy and abdominal plain computed tomography (CT). We investigated the findings of colonoscopy, CT scan and histological examination. We assessed the total dosages of GF alongside the duration of ambulatory visit, the administration period of herbal medicine containing GF and pre-existing disease in order to compare MP cases and non-MP patients. RESULTS: Ten MP cases and 42 non-MP patients were analyzed. We summarized clinical findings of MP cases. All MP cases used more GF than non-MP patients and were administered more than approximately 5,000 grams of GF in cumulative dosage. CONCLUSIONS: This study indicated that excessive intake of GF contributes to and/or accelerates the development of MP suggesting that long-term usage of GF in excessive amounts increases the risk of MP.


Subject(s)
Gardenia/chemistry , Mesenteric Veins/drug effects , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plants, Medicinal/chemistry , Vascular Calcification/chemically induced , Aged , Female , Fruit/chemistry , Humans , Male , Mesenteric Veins/physiopathology , Middle Aged , Phytotherapy/statistics & numerical data , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Vascular Calcification/epidemiology
2.
J Gastroenterol ; 40(5): 504-10, 2005 May.
Article in English | MEDLINE | ID: mdl-15942716

ABSTRACT

BACKGROUND: Pancreatic cancer cells often show resistance to hypoxia-mediated apoptosis, but the molecular mechanism underlying that resistance remains unknown. The purpose of the present study, therefore, was to examine the role of epigenetic gene alteration in the resistance to hypoxia-mediated apoptosis among pancreatic cancer cells. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to examine the expression of five genes associated with hypoxia-mediated apoptosis (PUMA, Caspase-8 [CASP8], APAF-1, BNIP3, and BNIP3L) in a panel of pancreatic cancer cell lines. Protein expression was examined by Western blot analysis, using lysates from cells incubated under normoxic or hypoxic conditions. The methylation status of the genes was determined using bisulfite-PCR and sequencing. The percentages of cells that were apoptotic were determined using flow cytometry. RESULTS: Under normoxic conditions, the expression of the BNIP3 gene varied among the 12 pancreatic cancer cell lines tested, with 50% of them showing no BNIP3 expression at all, whereas expression of the other four genes was readily detected in all 12 cell lines. DNA methylation of BNIP3's CpG island in the region around the transcription start site of the gene was closely associated with its silencing. The expression of BNIP3 was restored by the methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-dC), as was the hypoxia-mediated pancreatic cancer cell death. CONCLUSIONS: BNIP3 expression is silenced in some pancreatic cancer cells by the methylation of its CpG island. Demethylation of BNIP3, using a methyltransferase inhibitor, restores the gene's expression and induces hypoxia-mediated cell death. BNIP3 may thus be a useful target for new therapies aimed at treating pancreatic cancer.


Subject(s)
Cell Death/drug effects , Deoxycytidine/pharmacology , Membrane Proteins/drug effects , Membrane Proteins/genetics , Proto-Oncogene Proteins/drug effects , Proto-Oncogene Proteins/genetics , Sulfites/pharmacology , Base Sequence , Blotting, Western , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Flow Cytometry , Gene Expression Regulation , Humans , Hypoxia , Membrane Proteins/metabolism , Methylation/drug effects , Molecular Sequence Data , Pancreatic Neoplasms , Proto-Oncogene Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Up-Regulation
3.
Clin Cancer Res ; 11(3): 1021-7, 2005 Feb 01.
Article in English | MEDLINE | ID: mdl-15709167

ABSTRACT

BNIP3 protein is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. To examine its role in the progression of gastrointestinal cancer, we examined the expression and DNA methylation status of BNIP3 gene in a panel of colorectal and gastric cancer cell lines. BNIP3 was not expressed in 14 of the 24 cell lines tested, and its absence was not caused by gene mutation or by altered expression of hypoxia inducible factor-1, a key transcription factor that regulates BNIP3 expression. On the other hand, methylation of the 5' CpG island of BNIP3 was closely correlated with silencing the gene. Moreover, treating methylated cells with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored hypoxia-induced expression of BNIP3 mRNA and protein, which in turn led to cell death. Aberrant methylation of BNIP3 was also detected in 66% of primary colorectal and 49% of primary gastric cancers, but not in normal tissue samples collected from areas adjacent to the tumors. Apparently, epigenetic alteration of BNIP3 is a frequent and cancer-specific event, which suggests that inactivation of BNIP3 likely plays a key role in the progression of some gastrointestinal cancers and that it may be a useful molecular target for therapy.


Subject(s)
Azacitidine/analogs & derivatives , Colorectal Neoplasms/genetics , DNA Methylation , Gene Silencing , Membrane Proteins/genetics , Proto-Oncogene Proteins/genetics , Stomach Neoplasms/genetics , Acetylation , Azacitidine/pharmacology , Base Sequence , Blotting, Western , Cell Line, Tumor , Colorectal Neoplasms/pathology , CpG Islands/genetics , DNA Modification Methylases/antagonists & inhibitors , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , DNA, Neoplasm/metabolism , Decitabine , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylases/metabolism , Histones/metabolism , Humans , Membrane Proteins/metabolism , Microscopy, Confocal , Microscopy, Fluorescence , Proto-Oncogene Proteins/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Stomach Neoplasms/pathology
4.
Clin Cancer Res ; 9(17): 6410-8, 2003 Dec 15.
Article in English | MEDLINE | ID: mdl-14695142

ABSTRACT

PURPOSE: Aberrant methylation of CpG islands can be a good molecular marker for identifying genes inactivated in cancer. We found the proapoptotic gene HRK to be a target for hypermethylation in human cancers and examined the role of such methylation in silencing the gene's expression. EXPERIMENTAL DESIGN: Methylation of HRK was evaluated by bisulfite-PCR and bisulfite sequencing in a group of colorectal and gastric cancer cell lines and primary cancers. Gene expression and histone acetylation were examined by reverse transcription-PCR and chromatin immunoprecipitation analyses, respectively. Apoptosis of cancer cells after treatment with a DNA methyltransferase inhibitor and/or histone deacetylase inhibitor was examined with fluorescence-activated cell-sorting analysis. RESULTS: The region around the HRK transcription start site was methylated in 36% of colorectal and 32% of gastric cancer cell lines and was closely associated with loss of expression in those cell types. HRK expression was restored by treatment with a methyltransferase inhibitor, 5-aza-deoxycytidine, and enhanced further by addition of histone deacetylase inhibitor trichostatin A or depsipeptide. Such restoration of HRK expression was well correlated with induction of apoptosis and enhancement of Adriamycin-induced apoptosis. Expression of other proapoptotic genes, including BAX, BAD, BID, and PUMA, was unaffected by treatment with 5-aza-deoxycytidine. Aberrant methylation of HRK was also frequently detected in primary colorectal cancers that showed methylation of multiple genes, including p16INK4A and hMLH1, and was associated with wild-type p53. CONCLUSION: HRK methylation can be a useful molecular target for cancer therapy in a subset of colorectal and gastric cancers.


Subject(s)
Azacitidine/analogs & derivatives , Colorectal Neoplasms/genetics , Depsipeptides , Neuropeptides/metabolism , Stomach Neoplasms/genetics , Apoptosis , Apoptosis Regulatory Proteins , Azacitidine/pharmacology , Biomarkers, Tumor , Cell Line, Tumor , Cell Separation , Chromatin/metabolism , Colorectal Neoplasms/metabolism , CpG Islands , DNA Methylation , Decitabine , Doxorubicin/pharmacology , Flow Cytometry , Histone Deacetylase Inhibitors , Histones/metabolism , Humans , Hydroxamic Acids/pharmacology , Models, Genetic , Oligopeptides/pharmacology , Polymerase Chain Reaction , Precipitin Tests , Reverse Transcriptase Polymerase Chain Reaction , Stomach Neoplasms/metabolism , Sulfites/chemistry
5.
Genetics ; 165(3): 1551-68, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14668402

ABSTRACT

A consensus map for sugi (Cryptomeria japonica) was constructed by integrating linkage data from two unrelated third-generation pedigrees, one derived from a full-sib cross and the other by self-pollination of F1 individuals. The progeny segregation data of the first pedigree were derived from cleaved amplified polymorphic sequences, microsatellites, restriction fragment length polymorphisms, and single nucleotide polymorphisms. The data of the second pedigree were derived from cleaved amplified polymorphic sequences, isozyme markers, morphological traits, random amplified polymorphic DNA markers, and restriction fragment length polymorphisms. Linkage analyses were done for the first pedigree with JoinMap 3.0, using its parameter set for progeny derived by cross-pollination, and for the second pedigree with the parameter set for progeny derived from selfing of F1 individuals. The 11 chromosomes of C. japonica are represented in the consensus map. A total of 438 markers were assigned to 11 large linkage groups, 1 small linkage group, and 1 nonintegrated linkage group from the second pedigree; their total length was 1372.2 cM. On average, the consensus map showed 1 marker every 3.0 cM. PCR-based codominant DNA markers such as cleaved amplified polymorphic sequences and microsatellite markers were distributed in all linkage groups and occupied about half of mapped loci. These markers are very useful for integration of different linkage maps, QTL mapping, and comparative mapping for evolutional study, especially for species with a large genome size such as conifers.


Subject(s)
Cryptomeria/genetics , Expressed Sequence Tags , Genetic Linkage , Microsatellite Repeats/genetics , Pedigree , Base Sequence , DNA Primers , Genetic Markers
SELECTION OF CITATIONS
SEARCH DETAIL